Merck closes Rosetta Inpharmatics acquisition July 19. The $620 mil. deal was announced in May (1"The Pink Sheet" May 14, p.10)
You may also be interested in...
Merck's $620 mil. acquisition offer for Rosetta Inpharmatics will scale up Merck's genomics research efforts - and may also scale up its tolerance for mergers and acquisitions.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials